Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Viralytics strengthens portfolio

Facebook Twitter LinkedIn Email Comments
In Sydney, Australia, Viralytics Ltd. has received a US patent for the use of Echoviruses, including the proprietary Evatak formulation of Echovirus Type 1, to treat all cancers expressing the integrin a2b1 molecule. Included are ovarian, prostate and gastric forms, all of which express high levels of the molecule on their surfaces. The patent provides the company with the exclusive use of the viruses in this manner until 2023, and it strengthens Viralytics’ intellectual property portfolio.

Photonics Spectra
Jun 2009
cancermoleculePatent NewsSlices from the Breadboardvirus

Comments
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x Subscribe to Photonics Spectra magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.